AGP Executive Report

Vaccine Trial: Danish researchers’ hepatitis B study in Guinea-Bissau has been approved despite strong ethical objections. It plans to withhold the birth-dose vaccine from half of 14,000 newborns for six weeks, prompting warnings about preventable infection risks. Heart Health: A Denmark-Spain study found silent artery plaque in 57% of 16,800 adults, including about one in 13 aged 18–29, showing that cardiovascular disease can begin before symptoms. Obesity Treatment: Zealand Pharma and Roche’s experimental drug helped participants lose up to 9.2% of their body weight in a mid-stage trial, adding to Denmark’s growing role in obesity medicine. Patient Safety: Denmark warned against unauthorised Botox treatments, highlighting the risks of unapproved procedures.

Budget & Care: Denmark’s 2027 budget proposal adds 2.3 billion kroner for regions and starts a phased rollout of state-funded dental care for early retirees and vulnerable groups, alongside cuts to student grants. Heart Health: A study of 16,800 adults in Denmark and Spain found silent artery plaque in 57%; about one in 13 participants aged 18–29 had signs of plaque. Pregnancy at Work: Danish-led research linked each hour of forward-bending work during pregnancy to a 36% higher miscarriage risk, while walking was associated with an 18% increase. Research Ethics: The University of Southern Denmark approved a Guinea-Bissau hepatitis B trial that would withhold the birth-dose vaccine from half the newborns, despite strong objections to the study’s ethics. Salon Safety: Tests in Danish hair salons found nickel-releasing tools in more than a third of salons and cobalt-releasing tools in about one fifth, raising concerns about occupational exposure.

Queen Margrethe: Denmark’s former monarch, 86, made her first major public appearance since a September hospital stay, joining the royal family at a concert in Fredensborg. Treatment Safety: Danish authorities have issued a warning about unauthorised Botox treatment. Obesity Research: Zealand Pharma’s experimental obesity drug helped patients lose up to 9.2% of body weight in a mid-stage trial, but analysts were less impressed by its effect on blood sugar in patients with diabetes. Healthy Nordic Diet: A study of more than 64,000 Swedish adults linked closer adherence to the Nordic diet with a modestly lower risk of death over 24 years; the findings are observational. Young People’s Mental Health: A Swedish twin study found family factors may explain much of the link between screen use and mental health problems, with the clearest associations involving interactive screen activities during adolescence.

Patient Safety: Denmark warned against Botox injections from unauthorised providers after six people in Zealand were hospitalised with suspected serious poisoning. Indoor Air: Aarhus University research highlights candle burning as a major source of indoor ultrafine-particle pollution—a notable concern in Denmark, where candle use is widespread. Digital Health: A new European study of remote monitoring for adults with myasthenia gravis has enrolled its first patient; Denmark is among five participating countries. Obesity Research: A mid-stage trial of an obesity drug developed by Zealand Pharma and Roche reported weight loss of up to 9.2%. Vaccine Demand: Bavarian Nordic raised its 2026 forecast after stronger travel-health sales, driven in part by increased US demand for rabies vaccines.

Data Security: Unauthorized searches of Denmark’s Central Person Register exposed names, addresses and CPR numbers linked to about 8.8 million people. The breach has prompted a security review and a warning not to use CPR numbers alone to verify identity; they are also used to access healthcare and other public services. Obesity Research: Zealand Pharma said its experimental drug petrelintide helped trial participants with obesity and type 2 diabetes lose up to 9.2% of body weight over 28 weeks, compared with 2% on placebo. The Danish company and Roche have begun late-stage trials. Cancer Treatment: A Dutch court ordered MSD to stop selling injectable Keytruda in Denmark and seven other European markets, finding that the product infringed a Halozyme patent. Greenlandic Women’s Rights: UN experts warned that a disputed report on Denmark’s history of forced contraception of Inuit women and girls could undermine accountability and remedy, stressing the need for an accurate record grounded in survivors’ experiences.

Cancer Treatment: Denmark’s Genmab rose after a late-stage trial found its combination with AbbVie’s epcoritamab significantly improved progression-free survival for patients with newly diagnosed diffuse large B-cell lymphoma. Novo Nordisk: The US FDA extended its review of the company’s haemophilia A drug, citing manufacturing issues. Parkinson’s Research: Lundbeck reported gains in “good ON-time” in a small Phase 1b study of its oral drug Lu AF28996; a Phase 2 trial is now underway. Safer Hospital Care: Danish sterilisation provider Sterilcentral is using AI-powered digital twins to improve the cleaning and delivery of surgical instruments to hospitals. Eye Health: Denmark’s Breye Therapeutics raised €67.5 million to advance oral treatments for early-stage retinal diseases. Childhood Obesity: New WHO guidance says medication may be considered for some 10- to 19-year-olds only when supervised lifestyle support has not worked; it is not recommended for children under 10.

Data Breach in Denmark’s CPR: Denmark confirmed a “deeply serious incident” after hackers accessed names, addresses and CPR numbers tied to about 8.8 million people via a third-party’s legitimate access, with the scale only spotted after abnormal activity showed up in invoicing. Infectious Disease Watch: The WHO says a suspected pneumonic plague case in Russia poses a very low risk outside the country, after a lab worker’s pneumonia death; Russia reports no plague among contacts and no sign of sustained person-to-person spread. Healthcare Policy & Access: Alberta sent officials to Sweden and Denmark to study public/private doctor models as it rolls out a dual-practice approach, drawing criticism over potential conflicts with Canada’s health rules. Cancer Treatment Update: Genmab and AbbVie report epcoritamab plus R-CHOP cut progression-or-death risk by 51% in newly diagnosed diffuse large B-cell lymphoma, setting up regulator discussions. Denmark Pharma News: The FDA extended its review of Novo’s hemophilia A drug denecimig due to manufacturing facility remediation, with no efficacy/safety issues cited.

Data Breach Shock: Denmark’s Central Person Register (CPR) was accessed via a third-party firm, exposing names, addresses and CPR numbers for 8.8 million people—health IDs included—prompting a “deeply serious” response and a full security review. Cancer Breakthrough: Genmab and AbbVie report epcoritamab plus R-CHOP cut progression-or-death risk by 51% in newly diagnosed diffuse large B-cell lymphoma, a potential frontline shift for patients. Kidney & Weight-Loss Drugs: New analyses weigh whether semaglutide-related creatinine changes can falsely improve eGFR readings; one Danish study saw a small creatinine rise, while another found no link to GFR estimate inflation. Public Health Watch: WHO says a possible pneumonic plague case in Russia is a “very low” risk outside the country, as investigators assess a lab worker’s death. Weight-Loss Next Wave: Early results on amylin-based obesity drugs like petrelintide suggest similar appetite effects with fewer gastrointestinal side effects than GLP-1s. Healthcare Tech & Security: Asos is investigating claims of a hack after app notifications told customers a cloud database was “fully compromised.”

Weight-loss drug race: A new international trial reports amylin-based obesity meds (petrelintide) may cause fewer gastrointestinal side effects than popular GLP-1s, with average weight loss around 10% over 42 weeks. Cancer care breakthrough: Danish biotech Genmab and AbbVie say epcoritamab plus R-CHOP cut the risk of progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma, with safety broadly matching known profiles. Blood cancer prevention angle: A phase 2 trial (EVITA) suggests correcting vitamin C deficiency in people with CCUS or MDS may reduce adverse events and shift inflammation-related signals, with a possible survival hint. Routine testing guidance: New research from a large dataset suggests strict fasting before many blood tests may be unnecessary, with meaningful effects limited to certain measures like glucose and triglycerides. Denmark data security: Denmark reports a major breach of the Central Person Register, exposing names, addresses and CPR numbers for about 8.8 million people after misuse of legitimate access by a third-party company. Women’s health spotlight: Freya Biosciences is named a Fierce Biotech “Fierce 15” for 2026 after positive early results for an immunology therapy aimed at IVF-related embryo implantation failure.

Aspirin Trial Update (Cancer Care): The Scandinavian ASAC phase 3 trial found aspirin did not improve disease-free survival after curative-intent treatment of colorectal cancer liver metastases, contrasting with earlier benefits seen in non-metastatic disease. Biotech for Rare Muscle Disease (Drug Development): BridgeBio presented 12-month exploratory cardiac results for oral BBP-418 in FKRP-related limb-girdle muscular dystrophy type 2I/R9, reporting normalization of a heart injury marker in the treatment arm and FDA Priority Review progress. Fertility & Women’s Health (Pipeline Recognition): ReproNovo was named a Fierce 15 biotech company, highlighting oral therapies for male infertility and embryo transfer outcomes, plus a program targeting adenomyosis. Weight-Loss Science & Nobel Buzz (Global Health): Nobel medicine speculation spotlights appetite-hormone and GLP-1 research tied to drugs like Ozempic and Mounjaro, with Danish physician Jens Juul Holst among frequently mentioned names. Denmark-Linked Research (Metabolism): University of Copenhagen researchers identified SLC25A34 as a key protein linking body clock, cold exposure, and brown fat activity—potentially informing future fat-burning strategies. Maternity Oversight (Care Quality): Scotland’s maternity review will include intensive visits at about half of health boards, using interviews and community listening to shape improvements.

Women’s Health & Trust: A new report traces how the contraceptive pill—once a symbol of liberation—has lost ground in parts of Europe, with France seeing a sharp drop in pill use since 2005 as IUDs rise. Gut Health & Ageing: Researchers report a newly identified decline in nerve-to-muscle signaling with age, offering a fresh angle on why strength drops in older adults. Crohn’s Surge: Coverage highlights rising Crohn’s rates among young people in the US and links the trend to modern lifestyle and childhood exposures, while noting the disease’s long-term cancer risk. Obesity Drug Race: Lilly’s mid-stage obesity combo (EloraTZP) is reported to outperform Zepbound in people with diabetes, adding to the fast-moving GLP-1/dual-agonist competition. Health Financing in Africa: President John Mahama urges “health sovereignty,” arguing healthcare should be treated as an investable growth sector, not just a budget cost. Denmark-linked Pharma: Danish biotech Breye Therapeutics raises €67.5m to advance oral therapies for early retinal diseases. Cancer Treatment Update: Genmab reports durable responses for rinatabart sesutecan in platinum-resistant ovarian cancer.

Cancer Drug Update (Denmark): Genmab reported Part C Phase 1/2 RAINFOL™-01 results for rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer, with a confirmed objective response rate of 45.9% and median progression-free survival of 9.5 months, including responses even in low FRα expressers. Metabolic Science (Denmark): University of Copenhagen researchers highlighted SLC25A34 as a “master switch” linking the body clock, cold exposure and diet to brown-fat energy use; a Denmark-led EVITA trial also found 1,000 mg/day vitamin C in people at risk of blood cancer changed inflammatory signals and reduced some complications. Public Health Policy (Africa): President John Dramani Mahama urged African leaders to treat health as an investable economic sector to build “health sovereignty,” arguing health spending boosts jobs, manufacturing and stability. Cardiovascular Risk: A Denmark- and Spain-led study found silent artery plaque in 57.1% of adults without known cardiovascular disease, rising from about 1 in 13 under 30 to nearly all by age 60–70. Care Access & Safety: A doctor-led GLP-1 service in South Africa is expanding virtual access amid regulator crackdowns on illegal compounding.

Health Sovereignty Push: African Union forum keynote speaker President John Dramani Mahama urged leaders to treat healthcare as an investable, high-growth sector to build “health sovereignty” and protect economic growth for 1.4 billion Africans. Cardiovascular Screening Gap: A large international study found silent artery plaque in 1 in 13 adults aged 18–29 and in 57% overall—suggesting heart disease starts far earlier than many realize. Early Detection Tech: Yale researchers report an AI-read ECG that can flag people at risk of amyloid cardiomyopathy, aiming to prompt earlier follow-up before irreversible damage. Breast Cancer Access: Eurostat data show Denmark leads mammography participation (82.1% of women 50–69 screened), while Cyprus has high unit availability but low screening uptake. Denmark-linked Pharma Update: Novo Nordisk said the US FDA extended review of its hemophilia A drug denecimig due to manufacturing remediation, with no new decision date but no change to its 2026 outlook. Obesity Drug Pipeline: Zealand Pharma’s survodutide results and stock concerns continue to ripple, as developers race to differentiate next-gen weight-loss options. Disability & Care Policy Watch (UK): Reports say UK plans could cut disability benefits for under-25s and reshape adult social care funding—an issue with knock-on effects for health services.

Novo Nordisk FDA delay: The US FDA extended its review of Novo’s hemophilia A drug denecimig because remediation is still ongoing at a manufacturing site, with no new decision date yet; Novo says safety/efficacy data aren’t flagged and the delay won’t change its 2026 outlook. Breye Therapeutics funding: Denmark’s Breye Therapeutics raised €67.5m to advance oral therapies for early retinal diseases, with Novo Holdings backing. Vitamin C trial in blood cancer risk: Denmark-and-US EVITA phase 2 results suggest vitamin C didn’t change the main cancer-growth measure, but did shift inflammatory signaling and was linked to fewer anemia, pneumonia, arthritis and internal bleeding cases (with more GI problems). AI ECG for amyloid: A Yale-led JAMA study reports an AI read of routine ECG photos can flag people at risk of amyloid cardiomyopathy earlier, aiming to guide who needs further imaging. Breast screening access: Eurostat data show Denmark leads on mammography participation (82.1%), while Cyprus has high unit availability but low screening uptake. PFAS spotlight: A Croatian report highlights “forever chemicals” concerns, with one participant reporting the highest PFAS levels among tested subjects. Danish ethics: Denmark’s ethics council recommends abolishing anonymous sperm and egg donation. Maternity litigation pressure: A UK-focused piece argues maternity services face an unsustainable litigation problem.

Novo Nordisk & FDA: The US FDA has extended its review of Novo Nordisk’s experimental hemophilia A drug denecimig due to ongoing manufacturing remediation, with no new safety or effectiveness concerns; Novo still targets a US launch in the first half of 2027. Danish biotech funding: Breye Therapeutics raised €67.5m in an oversubscribed Series A to advance danegaptide, an oral treatment for early diabetic retinopathy. Cancer vaccine update (Denmark-based): Evaxion will present new immune data for its personalized cancer vaccine EVX-01 at SITC 2026, including systemic effects when combined with pembrolizumab. Local care workforce: Frederiksberg discussed Filipino recruitment for Denmark’s elder-care sector with the Philippine ambassador, as municipalities face ongoing staffing pressure. Brain-tech research: DTU and partners unveiled a needle-thin microfluidic brain implant (mAxialtrode) designed to record, deliver drugs, and stimulate multiple brain regions with reduced tissue damage. Clinical evidence (cardio): A Scandinavian trial found no benefit of aspirin after treatment of colorectal cancer liver metastases. Public health & policy: Denmark’s ethics council recommends abolishing anonymous sperm and egg donation.

Danish Health Tech Breakthrough: Researchers at DTU and the University of Copenhagen unveiled a needle-thin microfluidic brain implant that can record neural activity, deliver drugs, and stimulate multiple brain regions—aimed at advancing epilepsy research and future therapies. Neuro & Pharma Pipeline: Lundbeck will present new movement-disorders data at MDS 2026, including Phase III results for amlenetug in multiple system atrophy and additional Parkinson’s programme updates. Local Life-Sciences Deal: Samfara completed its acquisition of Chr. Olesen Synthesis near Copenhagen, expanding controlled-substance API manufacturing for medicines including buprenorphine and ADHD treatments. Weight-Loss Drug Science: A Danish study suggests more people with overweight could benefit from GLP-1s for heart protection, while separate research in the US reports a sharp rise in postpartum GLP-1 prescriptions. Public Health & Screening: A Europe-wide project reports that type 1 diabetes screening in children can be implemented across countries, supporting earlier detection strategies. Workplace Wellbeing: ISS and Tryg signed a new integrated facility-services partnership across Scandinavia, starting in 2027. AI & Safety: A study says AI-written text can evade detection tools using a simple method, raising new concerns for content rules.